Thus, the pan-HDAC inhibitor resminostat was shown to induce the reversion of stem-like properties in HCC cells [120] and the HDAC inhibitor belinostat was reported to improve the antitumor activity of anti-cytotoxic T lymphocyte antigen 4 (CTLA4) antibody in combination or not with anti-programmed cell death protein 1 (PD-1) therapy in a subcutaneous Hepa129 murine HCC model [121]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.